Key clinical point: A low baseline albumin level is significantly associated with hyperprogressive disease (HPD) development and worse survival outcomes after programmed cell death-1 (PD-1) blockade in patients with advanced gastric cancer (AGC).

Major finding: The optimal albumin cut-off value for predicting HPD was <3.25 mg/dL, with an area under the receiver operating curve of 0.7708 (P  =  .0022). Patients with albumin levels of <3.25 mg/dL had worse progression-free (hazard ratio [HR] 1.928; 95% CI 1.289-2.885) and overall (HR 1.833; 95% CI 1.211-2.774) survival.

Study details: This retrospective study included 169 patients with AGC who received PD-1 blockade therapy (nivolumab or pembrolizumab; n = 112) or irinotecan monotherapy (n = 57).

Disclosures: This study was funded by the National Research Foundation of Korea by the Korean government, among others. The authors declared no conflicts of interest.

Source: Kim CG et al. Hyperprogressive disease during PD-1 blockade in patients with advanced gastric cancer. Eur J Cancer. 2022;172:387-399 (Jul 13). Doi: 10.1016/j.ejca.2022.05.042

Key clinical point: A low baseline albumin level is significantly associated with hyperprogressive disease (HPD) development and worse survival outcomes after programmed cell death-1 (PD-1) blockade in patients with advanced gastric cancer (AGC).

Major finding: The optimal albumin cut-off value for predicting HPD was <3.25 mg/dL, with an area under the receiver operating curve of 0.7708 (P  =  .0022). Patients with albumin levels of <3.25 mg/dL had worse progression-free (hazard ratio [HR] 1.928; 95% CI 1.289-2.885) and overall (HR 1.833; 95% CI 1.211-2.774) survival.

Study details: This retrospective study included 169 patients with AGC who received PD-1 blockade therapy (nivolumab or pembrolizumab; n = 112) or irinotecan monotherapy (n = 57).

Disclosures: This study was funded by the National Research Foundation of Korea by the Korean government, among others. The authors declared no conflicts of interest.

Source: Kim CG et al. Hyperprogressive disease during PD-1 blockade in patients with advanced gastric cancer. Eur J Cancer. 2022;172:387-399 (Jul 13). Doi: 10.1016/j.ejca.2022.05.042

Key clinical point: A low baseline albumin level is significantly associated with hyperprogressive disease (HPD) development and worse survival outcomes after programmed cell death-1 (PD-1) blockade in patients with advanced gastric cancer (AGC).

Major finding: The optimal albumin cut-off value for predicting HPD was <3.25 mg/dL, with an area under the receiver operating curve of 0.7708 (P  =  .0022). Patients with albumin levels of <3.25 mg/dL had worse progression-free (hazard ratio [HR] 1.928; 95% CI 1.289-2.885) and overall (HR 1.833; 95% CI 1.211-2.774) survival.

Study details: This retrospective study included 169 patients with AGC who received PD-1 blockade therapy (nivolumab or pembrolizumab; n = 112) or irinotecan monotherapy (n = 57).

Disclosures: This study was funded by the National Research Foundation of Korea by the Korean government, among others. The authors declared no conflicts of interest.

Source: Kim CG et al. Hyperprogressive disease during PD-1 blockade in patients with advanced gastric cancer. Eur J Cancer. 2022;172:387-399 (Jul 13). Doi: 10.1016/j.ejca.2022.05.042

Key clinical point: Despite lower complete resection rates and a higher risk for recurrence, endoscopic resection (ER) offers similar long-term survival outcomes and serious adverse event (AE) rates and shorter hospital stays compared with surgery in early gastric cancer (EGC).

Major finding: The ER vs surgery group had a lower complete resection rate (risk difference [RD] −0.1; P < .00001), shorter length of hospital stay (P < .00001), higher rate of recurrence (RD 0.07; P < .00001), and comparable 5-year overall survival (RD −0.01; P  =  .38), cancer-specific survival (RD 0.01; P < .17), and serious AE rate (RD −0.03; P  =  .13).

Study details: This was a meta-analysis of 29 observational cohort studies (prospective: n = 2; retrospective: n = 27) involving 20,559 patients with EGC who underwent ER (n = 7709) or surgery (n = 12,850).

Disclosures: No source of funding was reported. The authors declared no conflicts of interest.

Source: Bestetti AM et al. endoscopic resection versus surgery in the treatment of early gastric cancer: A systematic review and meta-analysis. Front Oncol. 2022;12:939244 (Jul 12). Doi: 10.3389/fonc.2022.939244

Key clinical point: Despite lower complete resection rates and a higher risk for recurrence, endoscopic resection (ER) offers similar long-term survival outcomes and serious adverse event (AE) rates and shorter hospital stays compared with surgery in early gastric cancer (EGC).

Major finding: The ER vs surgery group had a lower complete resection rate (risk difference [RD] −0.1; P < .00001), shorter length of hospital stay (P < .00001), higher rate of recurrence (RD 0.07; P < .00001), and comparable 5-year overall survival (RD −0.01; P  =  .38), cancer-specific survival (RD 0.01; P < .17), and serious AE rate (RD −0.03; P  =  .13).

Study details: This was a meta-analysis of 29 observational cohort studies (prospective: n = 2; retrospective: n = 27) involving 20,559 patients with EGC who underwent ER (n = 7709) or surgery (n = 12,850).

Disclosures: No source of funding was reported. The authors declared no conflicts of interest.

Source: Bestetti AM et al. endoscopic resection versus surgery in the treatment of early gastric cancer: A systematic review and meta-analysis. Front Oncol. 2022;12:939244 (Jul 12). Doi: 10.3389/fonc.2022.939244

Key clinical point: Despite lower complete resection rates and a higher risk for recurrence, endoscopic resection (ER) offers similar long-term survival outcomes and serious adverse event (AE) rates and shorter hospital stays compared with surgery in early gastric cancer (EGC).

Major finding: The ER vs surgery group had a lower complete resection rate (risk difference [RD] −0.1; P < .00001), shorter length of hospital stay (P < .00001), higher rate of recurrence (RD 0.07; P < .00001), and comparable 5-year overall survival (RD −0.01; P  =  .38), cancer-specific survival (RD 0.01; P < .17), and serious AE rate (RD −0.03; P  =  .13).

Study details: This was a meta-analysis of 29 observational cohort studies (prospective: n = 2; retrospective: n = 27) involving 20,559 patients with EGC who underwent ER (n = 7709) or surgery (n = 12,850).

Disclosures: No source of funding was reported. The authors declared no conflicts of interest.

Source: Bestetti AM et al. endoscopic resection versus surgery in the treatment of early gastric cancer: A systematic review and meta-analysis. Front Oncol. 2022;12:939244 (Jul 12). Doi: 10.3389/fonc.2022.939244

Key clinical point: Preoperative plasma levels of the appetite-regulating gut hormone ghrelin may predict postoperative weight loss in patients who have undergone subtotal gastrectomy (STG) for gastric cancer.

Major finding: After adjusting for confounders, the area under the curve preoperative ghrelin level showed a significant negative correlation (ρ –0.8; P  =  .024) with the change in weight loss in the 4 months after STG.

Study details: Findings are from a prospective study including 13 patients aged 20-75 years with gastric cancer who underwent STG and 14 controls with no history of gastrointestinal surgery.

Disclosures: This study was supported by The Korean Society of Neurogastroenterology and Motility. The authors declared no conflicts of interest.

Source: Jung HK et al. Association between gut regulatory hormones and post-operative weight loss following gastrectomy in patients with gastric cancer. J Neurogastroenterol Motil. 2022;28(3):409-417 (Jul 30). Doi: 10.5056/jnm21145

Key clinical point: Preoperative plasma levels of the appetite-regulating gut hormone ghrelin may predict postoperative weight loss in patients who have undergone subtotal gastrectomy (STG) for gastric cancer.

Major finding: After adjusting for confounders, the area under the curve preoperative ghrelin level showed a significant negative correlation (ρ –0.8; P  =  .024) with the change in weight loss in the 4 months after STG.

Study details: Findings are from a prospective study including 13 patients aged 20-75 years with gastric cancer who underwent STG and 14 controls with no history of gastrointestinal surgery.

Disclosures: This study was supported by The Korean Society of Neurogastroenterology and Motility. The authors declared no conflicts of interest.

Source: Jung HK et al. Association between gut regulatory hormones and post-operative weight loss following gastrectomy in patients with gastric cancer. J Neurogastroenterol Motil. 2022;28(3):409-417 (Jul 30). Doi: 10.5056/jnm21145

Key clinical point: Preoperative plasma levels of the appetite-regulating gut hormone ghrelin may predict postoperative weight loss in patients who have undergone subtotal gastrectomy (STG) for gastric cancer.

Major finding: After adjusting for confounders, the area under the curve preoperative ghrelin level showed a significant negative correlation (ρ –0.8; P  =  .024) with the change in weight loss in the 4 months after STG.

Study details: Findings are from a prospective study including 13 patients aged 20-75 years with gastric cancer who underwent STG and 14 controls with no history of gastrointestinal surgery.

Disclosures: This study was supported by The Korean Society of Neurogastroenterology and Motility. The authors declared no conflicts of interest.

Source: Jung HK et al. Association between gut regulatory hormones and post-operative weight loss following gastrectomy in patients with gastric cancer. J Neurogastroenterol Motil. 2022;28(3):409-417 (Jul 30). Doi: 10.5056/jnm21145

Key clinical point: Computed tomography-determined low skeletal muscle mass (SMM) predicts worse overall survival (OS) in patients with gastric cancer and associated cachexia but not in those without cachexia.

Major finding: Patients with a low vs normal SMM had a significantly worse OS (P  =  .007). A low SMM significantly predicted worse OS in patients with cachexia (P  =  .009) but not in those without cachexia (P  =  .31).

Study details: This retrospective study included 255 adult patients with gastric cancer, of which 117 had low SMM including 49 patients with cachexia.

Disclosures: This study received no specific funding. The authors declared no conflicts of interest.

Source: Wan Q et al. CT-determined low skeletal muscle mass predicts worse overall survival of gastric cancer in patients with cachexia. Cancer Med. 2022 (Jul 18). Doi: 10.1002/cam4.5040

Key clinical point: Computed tomography-determined low skeletal muscle mass (SMM) predicts worse overall survival (OS) in patients with gastric cancer and associated cachexia but not in those without cachexia.

Major finding: Patients with a low vs normal SMM had a significantly worse OS (P  =  .007). A low SMM significantly predicted worse OS in patients with cachexia (P  =  .009) but not in those without cachexia (P  =  .31).

Study details: This retrospective study included 255 adult patients with gastric cancer, of which 117 had low SMM including 49 patients with cachexia.

Disclosures: This study received no specific funding. The authors declared no conflicts of interest.

Source: Wan Q et al. CT-determined low skeletal muscle mass predicts worse overall survival of gastric cancer in patients with cachexia. Cancer Med. 2022 (Jul 18). Doi: 10.1002/cam4.5040

Key clinical point: Computed tomography-determined low skeletal muscle mass (SMM) predicts worse overall survival (OS) in patients with gastric cancer and associated cachexia but not in those without cachexia.

Major finding: Patients with a low vs normal SMM had a significantly worse OS (P  =  .007). A low SMM significantly predicted worse OS in patients with cachexia (P  =  .009) but not in those without cachexia (P  =  .31).

Study details: This retrospective study included 255 adult patients with gastric cancer, of which 117 had low SMM including 49 patients with cachexia.

Disclosures: This study received no specific funding. The authors declared no conflicts of interest.

Source: Wan Q et al. CT-determined low skeletal muscle mass predicts worse overall survival of gastric cancer in patients with cachexia. Cancer Med. 2022 (Jul 18). Doi: 10.1002/cam4.5040

Key clinical point: In patients with early gastric cancer or gastric adenoma, the curative resection rate with endoscopic submucosal dissection (ESD) for lesions sized ≥5 cm is approximately two-thirds of that for lesions <5 cm; however, delayed perforation is more common in the former.

Major finding: In patients with ≥5 and <5 cm lesions, the curative resection rates were 65.6% and 91.5%, respectively, with the rate of delayed perforation being significantly higher in the former (1.6% and 0.1%, respectively; P  =  .019).

Study details: This multicenter retrospective study included 3410 ESD-treated  gastric lesions in patients aged ≥20 years with early gastric cancer or gastric adenoma and categorized them according to lesion size: <5 cm (n = 3282) and ≥5 cm (n = 128).

Disclosures: This study received no external funding. The authors declared no conflicts of interest.

Source: Chiba H et al. The feasibility and safety of endoscopic submucosal dissection of gastric lesions larger than 5 cm. Gastric Cancer. 2022 (Jul 25). Doi: 10.1007/s10120-022-01323-8

Key clinical point: In patients with early gastric cancer or gastric adenoma, the curative resection rate with endoscopic submucosal dissection (ESD) for lesions sized ≥5 cm is approximately two-thirds of that for lesions <5 cm; however, delayed perforation is more common in the former.

Major finding: In patients with ≥5 and <5 cm lesions, the curative resection rates were 65.6% and 91.5%, respectively, with the rate of delayed perforation being significantly higher in the former (1.6% and 0.1%, respectively; P  =  .019).

Study details: This multicenter retrospective study included 3410 ESD-treated  gastric lesions in patients aged ≥20 years with early gastric cancer or gastric adenoma and categorized them according to lesion size: <5 cm (n = 3282) and ≥5 cm (n = 128).

Disclosures: This study received no external funding. The authors declared no conflicts of interest.

Source: Chiba H et al. The feasibility and safety of endoscopic submucosal dissection of gastric lesions larger than 5 cm. Gastric Cancer. 2022 (Jul 25). Doi: 10.1007/s10120-022-01323-8

Key clinical point: In patients with early gastric cancer or gastric adenoma, the curative resection rate with endoscopic submucosal dissection (ESD) for lesions sized ≥5 cm is approximately two-thirds of that for lesions <5 cm; however, delayed perforation is more common in the former.

Major finding: In patients with ≥5 and <5 cm lesions, the curative resection rates were 65.6% and 91.5%, respectively, with the rate of delayed perforation being significantly higher in the former (1.6% and 0.1%, respectively; P  =  .019).

Study details: This multicenter retrospective study included 3410 ESD-treated  gastric lesions in patients aged ≥20 years with early gastric cancer or gastric adenoma and categorized them according to lesion size: <5 cm (n = 3282) and ≥5 cm (n = 128).

Disclosures: This study received no external funding. The authors declared no conflicts of interest.

Source: Chiba H et al. The feasibility and safety of endoscopic submucosal dissection of gastric lesions larger than 5 cm. Gastric Cancer. 2022 (Jul 25). Doi: 10.1007/s10120-022-01323-8

Key clinical point: Compared with radical surgery (RS) alone, RS combined with hyperthermic intraperitoneal chemotherapy (HIPEC) improves the relapse-free survival (RFS) in patients with locally advanced gastric cancer (LAGC).

Major finding: Patients receiving RS+HIPEC vs RS alone had a significantly longer median RFS (not reached vs 22.0 months; χ² 4.468; P  =  .035) and higher 2-year RFS rate (62.9% and 37.8%).

Study details: This retrospective study propensity score-matched patients with LAGC who received RS+HIPEC (n = 106) with those who received RS alone (n = 106).

Disclosures: This study was sponsored by the National Nature Science Foundation of China. The authors declared no conflicts of interest.

Source: Shen C et al. Comparative study of the efficacy and safety of radical surgery with or without hyperthermic intraperitoneal chemotherapy in locally advanced gastric cancer: A propensity score-matching analysis. Ann Surg Oncol. 2022 (Aug 8). Doi: 10.1245/s10434-022-12348-9

Key clinical point: Compared with radical surgery (RS) alone, RS combined with hyperthermic intraperitoneal chemotherapy (HIPEC) improves the relapse-free survival (RFS) in patients with locally advanced gastric cancer (LAGC).

Major finding: Patients receiving RS+HIPEC vs RS alone had a significantly longer median RFS (not reached vs 22.0 months; χ² 4.468; P  =  .035) and higher 2-year RFS rate (62.9% and 37.8%).

Study details: This retrospective study propensity score-matched patients with LAGC who received RS+HIPEC (n = 106) with those who received RS alone (n = 106).

Disclosures: This study was sponsored by the National Nature Science Foundation of China. The authors declared no conflicts of interest.

Source: Shen C et al. Comparative study of the efficacy and safety of radical surgery with or without hyperthermic intraperitoneal chemotherapy in locally advanced gastric cancer: A propensity score-matching analysis. Ann Surg Oncol. 2022 (Aug 8). Doi: 10.1245/s10434-022-12348-9

Key clinical point: Compared with radical surgery (RS) alone, RS combined with hyperthermic intraperitoneal chemotherapy (HIPEC) improves the relapse-free survival (RFS) in patients with locally advanced gastric cancer (LAGC).

Major finding: Patients receiving RS+HIPEC vs RS alone had a significantly longer median RFS (not reached vs 22.0 months; χ² 4.468; P  =  .035) and higher 2-year RFS rate (62.9% and 37.8%).

Study details: This retrospective study propensity score-matched patients with LAGC who received RS+HIPEC (n = 106) with those who received RS alone (n = 106).

Disclosures: This study was sponsored by the National Nature Science Foundation of China. The authors declared no conflicts of interest.

Source: Shen C et al. Comparative study of the efficacy and safety of radical surgery with or without hyperthermic intraperitoneal chemotherapy in locally advanced gastric cancer: A propensity score-matching analysis. Ann Surg Oncol. 2022 (Aug 8). Doi: 10.1245/s10434-022-12348-9

Key clinical point: Compared with radical surgery (RS) alone, RS combined with hyperthermic intraperitoneal chemotherapy (HIPEC) improves the relapse-free survival (RFS) in patients with locally advanced gastric cancer (LAGC).

Major finding: Patients receiving RS+HIPEC vs RS alone had a significantly longer median RFS (not reached vs 22.0 months; χ² 4.468; P  =  .035) and higher 2-year RFS rate (62.9% and 37.8%).

Study details: This retrospective study propensity score-matched patients with LAGC who received RS+HIPEC (n = 106) with those who received RS alone (n = 106).

Disclosures: This study was sponsored by the National Nature Science Foundation of China. The authors declared no conflicts of interest.

Source: Shen C et al. Comparative study of the efficacy and safety of radical surgery with or without hyperthermic intraperitoneal chemotherapy in locally advanced gastric cancer: A propensity score-matching analysis. Ann Surg Oncol. 2022 (Aug 8). Doi: 10.1245/s10434-022-12348-9

Key clinical point: Compared with radical surgery (RS) alone, RS combined with hyperthermic intraperitoneal chemotherapy (HIPEC) improves the relapse-free survival (RFS) in patients with locally advanced gastric cancer (LAGC).

Major finding: Patients receiving RS+HIPEC vs RS alone had a significantly longer median RFS (not reached vs 22.0 months; χ² 4.468; P  =  .035) and higher 2-year RFS rate (62.9% and 37.8%).

Study details: This retrospective study propensity score-matched patients with LAGC who received RS+HIPEC (n = 106) with those who received RS alone (n = 106).

Disclosures: This study was sponsored by the National Nature Science Foundation of China. The authors declared no conflicts of interest.

Source: Shen C et al. Comparative study of the efficacy and safety of radical surgery with or without hyperthermic intraperitoneal chemotherapy in locally advanced gastric cancer: A propensity score-matching analysis. Ann Surg Oncol. 2022 (Aug 8). Doi: 10.1245/s10434-022-12348-9

Key clinical point: Compared with radical surgery (RS) alone, RS combined with hyperthermic intraperitoneal chemotherapy (HIPEC) improves the relapse-free survival (RFS) in patients with locally advanced gastric cancer (LAGC).

Major finding: Patients receiving RS+HIPEC vs RS alone had a significantly longer median RFS (not reached vs 22.0 months; χ² 4.468; P  =  .035) and higher 2-year RFS rate (62.9% and 37.8%).

Study details: This retrospective study propensity score-matched patients with LAGC who received RS+HIPEC (n = 106) with those who received RS alone (n = 106).

Disclosures: This study was sponsored by the National Nature Science Foundation of China. The authors declared no conflicts of interest.

Source: Shen C et al. Comparative study of the efficacy and safety of radical surgery with or without hyperthermic intraperitoneal chemotherapy in locally advanced gastric cancer: A propensity score-matching analysis. Ann Surg Oncol. 2022 (Aug 8). Doi: 10.1245/s10434-022-12348-9

Key clinical point: Endoscopic resection (ER) achieves favorable long-term survival outcomes in patients with early gastric cancer (EGC) in the real-world setting.

Major finding: The overall 5-year overall survival (OS) rate was 89.0% (95% CI 88.3%-89.6%). The lower limit of the 95% CI for the 5-year OS rate exceeded the threshold 5-year OS rate in all categories of pathological curability, including curative resection for expanded indications.

Study details: The data come from a multicenter prospective cohort study, J-WEB/EGC, that included 9054 patients with 10,021 EGC lesions who underwent ER.

Disclosures: This study was supported by the Japanese Ministry of Health, Labour, and Welfare, and Daiwa Securities Health Foundation. The authors declared no conflicts of interest.

Source: Suzuki H et al. Long-term survival after endoscopic resection for gastric cancer: Real-world evidence from a multicenter prospective cohort. Clin Gastroenterol Hepatol. 2022 (Aug 7). Doi: 10.1016/j.cgh.2022.07.029

Key clinical point: Endoscopic resection (ER) achieves favorable long-term survival outcomes in patients with early gastric cancer (EGC) in the real-world setting.

Major finding: The overall 5-year overall survival (OS) rate was 89.0% (95% CI 88.3%-89.6%). The lower limit of the 95% CI for the 5-year OS rate exceeded the threshold 5-year OS rate in all categories of pathological curability, including curative resection for expanded indications.

Study details: The data come from a multicenter prospective cohort study, J-WEB/EGC, that included 9054 patients with 10,021 EGC lesions who underwent ER.

Disclosures: This study was supported by the Japanese Ministry of Health, Labour, and Welfare, and Daiwa Securities Health Foundation. The authors declared no conflicts of interest.

Source: Suzuki H et al. Long-term survival after endoscopic resection for gastric cancer: Real-world evidence from a multicenter prospective cohort. Clin Gastroenterol Hepatol. 2022 (Aug 7). Doi: 10.1016/j.cgh.2022.07.029

Key clinical point: Endoscopic resection (ER) achieves favorable long-term survival outcomes in patients with early gastric cancer (EGC) in the real-world setting.

Major finding: The overall 5-year overall survival (OS) rate was 89.0% (95% CI 88.3%-89.6%). The lower limit of the 95% CI for the 5-year OS rate exceeded the threshold 5-year OS rate in all categories of pathological curability, including curative resection for expanded indications.

Study details: The data come from a multicenter prospective cohort study, J-WEB/EGC, that included 9054 patients with 10,021 EGC lesions who underwent ER.

Disclosures: This study was supported by the Japanese Ministry of Health, Labour, and Welfare, and Daiwa Securities Health Foundation. The authors declared no conflicts of interest.

Source: Suzuki H et al. Long-term survival after endoscopic resection for gastric cancer: Real-world evidence from a multicenter prospective cohort. Clin Gastroenterol Hepatol. 2022 (Aug 7). Doi: 10.1016/j.cgh.2022.07.029

Key clinical point: Laparoscopic distal gastrectomy was surgically and oncologically noninferior to open distal gastrectomy in patients with locally advanced gastric cancer throughout the 5-year follow-up period.

Major finding: Patients who underwent laparoscopic vs open distal gastrectomy had a significantly lower late complication rate (6.5% vs 11.0%; P  =  .01), but similar 5-year overall survival (88.9% vs 88.7%; P  =  .30) and relapse-free survival (79.5% vs 81.1%; P  =  .658) rates.

Study details: This study reports the 5-year follow-up results of the KLASS-02 trial that included 974 patients with locally advanced gastric cancer who underwent R0 resection by laparoscopic (n = 492) or open (n = 482) distal gastrectomy.

Disclosures: This study was sponsored by the National R&D Program for Cancer Control (NRDPCC), Ministry of Health and Welfare, Republic of Korea, and Ethicon Endo-Surgery, a Johnson & Johnson Company. Some authors reported receiving grants or personal fees from various sources, including NRDPCC and Ethicon Endo-Surgery.

Source: Son SY et al. Laparoscopic vs open distal gastrectomy for locally advanced gastric cancer: 5-year outcomes of the KLASS-02 randomized clinical trial. JAMA Surg. 2022 (Jul 20). Doi: 10.1001/jamasurg.2022.2749

Key clinical point: Laparoscopic distal gastrectomy was surgically and oncologically noninferior to open distal gastrectomy in patients with locally advanced gastric cancer throughout the 5-year follow-up period.

Major finding: Patients who underwent laparoscopic vs open distal gastrectomy had a significantly lower late complication rate (6.5% vs 11.0%; P  =  .01), but similar 5-year overall survival (88.9% vs 88.7%; P  =  .30) and relapse-free survival (79.5% vs 81.1%; P  =  .658) rates.

Study details: This study reports the 5-year follow-up results of the KLASS-02 trial that included 974 patients with locally advanced gastric cancer who underwent R0 resection by laparoscopic (n = 492) or open (n = 482) distal gastrectomy.

Disclosures: This study was sponsored by the National R&D Program for Cancer Control (NRDPCC), Ministry of Health and Welfare, Republic of Korea, and Ethicon Endo-Surgery, a Johnson & Johnson Company. Some authors reported receiving grants or personal fees from various sources, including NRDPCC and Ethicon Endo-Surgery.

Source: Son SY et al. Laparoscopic vs open distal gastrectomy for locally advanced gastric cancer: 5-year outcomes of the KLASS-02 randomized clinical trial. JAMA Surg. 2022 (Jul 20). Doi: 10.1001/jamasurg.2022.2749

Key clinical point: Laparoscopic distal gastrectomy was surgically and oncologically noninferior to open distal gastrectomy in patients with locally advanced gastric cancer throughout the 5-year follow-up period.

Major finding: Patients who underwent laparoscopic vs open distal gastrectomy had a significantly lower late complication rate (6.5% vs 11.0%; P  =  .01), but similar 5-year overall survival (88.9% vs 88.7%; P  =  .30) and relapse-free survival (79.5% vs 81.1%; P  =  .658) rates.

Study details: This study reports the 5-year follow-up results of the KLASS-02 trial that included 974 patients with locally advanced gastric cancer who underwent R0 resection by laparoscopic (n = 492) or open (n = 482) distal gastrectomy.

Disclosures: This study was sponsored by the National R&D Program for Cancer Control (NRDPCC), Ministry of Health and Welfare, Republic of Korea, and Ethicon Endo-Surgery, a Johnson & Johnson Company. Some authors reported receiving grants or personal fees from various sources, including NRDPCC and Ethicon Endo-Surgery.

Source: Son SY et al. Laparoscopic vs open distal gastrectomy for locally advanced gastric cancer: 5-year outcomes of the KLASS-02 randomized clinical trial. JAMA Surg. 2022 (Jul 20). Doi: 10.1001/jamasurg.2022.2749

Key clinical point: Patients with rheumatoid arthritis (RA) and low or moderate disease activity were at a higher risk for hospitalized infections compared with those in remission.

Major finding: Compared with patients attaining remission, patients attaining low disease activity (adjusted hazard ratio [aHR] 1.60; 95% CI 1.13-2.27) and moderate disease activity (aHR 1.83; 95% CI 1.29-2.61) were at a higher risk for hospitalized infections.

Study details: Findings are from a prospective observational cohort study including 3254 patients with moderate RA from the CorEvitas RA registry.

Disclosures: H Yun and JR Curtis declared receiving support from US National Institutes of Health/National Institute of Arthritis and Musculoskeletal and Skin Diseases. Two authors reported being employees and shareholders of CorEvitas LLC. Several authors reported receiving research funding from or serving on speakers bureaus or as consultants for various sources.

Source: Yun H et al. Rheumatoid arthritis disease activity and hospitalized infection in a large U.S. registry. Arthritis Care Res (Hoboken). 2022 (Jul 22). Doi: 10.1002/acr.24984

Key clinical point: Patients with rheumatoid arthritis (RA) and low or moderate disease activity were at a higher risk for hospitalized infections compared with those in remission.

Major finding: Compared with patients attaining remission, patients attaining low disease activity (adjusted hazard ratio [aHR] 1.60; 95% CI 1.13-2.27) and moderate disease activity (aHR 1.83; 95% CI 1.29-2.61) were at a higher risk for hospitalized infections.

Study details: Findings are from a prospective observational cohort study including 3254 patients with moderate RA from the CorEvitas RA registry.

Disclosures: H Yun and JR Curtis declared receiving support from US National Institutes of Health/National Institute of Arthritis and Musculoskeletal and Skin Diseases. Two authors reported being employees and shareholders of CorEvitas LLC. Several authors reported receiving research funding from or serving on speakers bureaus or as consultants for various sources.

Source: Yun H et al. Rheumatoid arthritis disease activity and hospitalized infection in a large U.S. registry. Arthritis Care Res (Hoboken). 2022 (Jul 22). Doi: 10.1002/acr.24984

Key clinical point: Patients with rheumatoid arthritis (RA) and low or moderate disease activity were at a higher risk for hospitalized infections compared with those in remission.

Major finding: Compared with patients attaining remission, patients attaining low disease activity (adjusted hazard ratio [aHR] 1.60; 95% CI 1.13-2.27) and moderate disease activity (aHR 1.83; 95% CI 1.29-2.61) were at a higher risk for hospitalized infections.

Study details: Findings are from a prospective observational cohort study including 3254 patients with moderate RA from the CorEvitas RA registry.

Disclosures: H Yun and JR Curtis declared receiving support from US National Institutes of Health/National Institute of Arthritis and Musculoskeletal and Skin Diseases. Two authors reported being employees and shareholders of CorEvitas LLC. Several authors reported receiving research funding from or serving on speakers bureaus or as consultants for various sources.

Source: Yun H et al. Rheumatoid arthritis disease activity and hospitalized infection in a large U.S. registry. Arthritis Care Res (Hoboken). 2022 (Jul 22). Doi: 10.1002/acr.24984